HUP0105226A2 - Eljárás a súlyos krónikus bronchitis (bronchiectasia) kezelésére egy aeroszol formában lévõ antibiotikummal - Google Patents

Eljárás a súlyos krónikus bronchitis (bronchiectasia) kezelésére egy aeroszol formában lévõ antibiotikummal

Info

Publication number
HUP0105226A2
HUP0105226A2 HU0105226A HUP0105226A HUP0105226A2 HU P0105226 A2 HUP0105226 A2 HU P0105226A2 HU 0105226 A HU0105226 A HU 0105226A HU P0105226 A HUP0105226 A HU P0105226A HU P0105226 A2 HUP0105226 A2 HU P0105226A2
Authority
HU
Hungary
Prior art keywords
treatment
chronic bronchitis
antibiotic
severe chronic
bronchiectasis
Prior art date
Application number
HU0105226A
Other languages
English (en)
Inventor
William R. Baker
Alan B. Montgomery
Original Assignee
Pathogenesis Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathogenesis Corporation filed Critical Pathogenesis Corporation
Publication of HUP0105226A2 publication Critical patent/HUP0105226A2/hu
Publication of HUP0105226A3 publication Critical patent/HUP0105226A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

A tal lm ny t rgy t egy, a súlyos krónikus bronchitis (bronchiectasia)kezelésére szolg ló elj r s képezi, mely egy koncentr lt antibiotikum-készítményt alkalmaz, mely az antibiotikumot a tüdő alveolusokat istartalmazó endobronchi lis terébe juttatja egy aeroszol vagy egy szraz por alakj ban, melynek t"meg tlagos tmérője túlnyomórészt 1 és 5mikron k"z"tt van. Az elj r s sor n az antibiotikumot olyan koncentrcióban alkalmazz k, mely 1-10000-szer magasabb, mint a célszervbenmért minim lis inhibitor-koncentr ció. Előny"sen, az elj r s sor n azaeroszol vagy sz raz por alakban lévő tobramycint endobronchi lisanjuttatj k be a pseudomonas-fertőzések kezelésére a súlyos krónikusbronchitisben (bronchiectasi ban) szenvedő betegeknél. Ó
HU0105226A 1998-12-17 1999-12-17 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic HUP0105226A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11298498P 1998-12-17 1998-12-17
PCT/US1999/030234 WO2000035461A1 (en) 1998-12-17 1999-12-17 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic

Publications (2)

Publication Number Publication Date
HUP0105226A2 true HUP0105226A2 (hu) 2002-04-29
HUP0105226A3 HUP0105226A3 (en) 2003-03-28

Family

ID=22346930

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0105226A HUP0105226A3 (en) 1998-12-17 1999-12-17 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic

Country Status (15)

Country Link
US (1) US6387886B1 (hu)
EP (1) EP1161247A4 (hu)
JP (1) JP2002532430A (hu)
CN (1) CN1348377A (hu)
AU (1) AU778797B2 (hu)
BR (1) BR9916296A (hu)
CA (1) CA2355775A1 (hu)
CH (1) CH693763A5 (hu)
CZ (1) CZ20012147A3 (hu)
HK (1) HK1043732A1 (hu)
HU (1) HUP0105226A3 (hu)
NO (1) NO328594B1 (hu)
PL (1) PL348812A1 (hu)
SI (1) SI20959A (hu)
WO (1) WO2000035461A1 (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2002231244B2 (en) 2000-12-27 2006-06-29 Gilead Sciences, Inc. Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
US7214364B2 (en) 2000-12-27 2007-05-08 Corus Pharma, Inc. Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
EP1598059A1 (en) * 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
AU2007202942B2 (en) * 2001-05-18 2010-05-27 Novartis Ag Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
PT1320355E (pt) * 2001-05-18 2006-08-31 Chiron Corp Sistema para administracao de uma formulacao de tobramicina
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
TWI324518B (en) * 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US8245708B2 (en) * 2002-05-07 2012-08-21 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
AU2003238846A1 (en) * 2002-05-31 2003-12-19 Childrens Hospital And Regional Medical Center Endobronchial delivery of antibiotic in individuals with impaired lung tissue or lung function
US6966649B2 (en) * 2002-08-12 2005-11-22 John H Shadduck Adaptive optic lens system and method of use
US20070128124A1 (en) * 2002-09-12 2007-06-07 Kraus Carl N Aerosolized capreomycin for inhibition of pulmonary tuberculosis
EP1560540A4 (en) * 2002-10-18 2008-03-19 Molichem Medicines Inc METHOD FOR TREATING DRY EYES WITH LANTIBIOTICS
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
EP2823820B1 (en) * 2002-10-29 2018-06-06 Insmed Incorporated Liposomes comprising an aminoglycoside for the treatment of pulmonary infections
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DK1673074T3 (da) * 2003-10-15 2007-05-07 Pari Gmbh Flydende præparat, indeholdende tobramycin
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
PT2266534E (pt) 2004-05-17 2012-10-09 Gilead Sciences Inc Combinação fosfomicina/aminoglicósido num aerossol para o tratamento de infecções respiratórias devidas a bactérias
DK1765288T3 (da) * 2004-06-18 2013-02-11 Novartis Ag Tobramycinpræparater til behandling af endobronchiale infektioner
BRPI0616642A2 (pt) * 2005-09-29 2011-06-28 Nektar Therapeutics formulações de antibióticos, doses unitárias, kits e métodos
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
AU2006322076C1 (en) 2005-12-08 2013-11-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
EP2012750B1 (en) * 2006-04-06 2018-02-21 Insmed Incorporated Methods for coacervation induced liposomal encapsulation and formulations thereof
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US8551534B2 (en) * 2007-10-10 2013-10-08 Parion Sciences, Inc. Inhaled hypertonic saline delivered by a heated nasal cannula
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
MX2011000405A (es) * 2008-07-18 2011-03-04 Prosonix Ltd Proceso para mejorar la cristalinidad.
BR112013000921A2 (pt) * 2010-07-12 2016-05-17 Xellia Pharmaceuticals Aps tratamento de infecções pulmonares pela administração de tobramicina por aerolização
US8689439B2 (en) 2010-08-06 2014-04-08 Abbott Laboratories Method for forming a tube for use with a pump delivery system
US8377001B2 (en) 2010-10-01 2013-02-19 Abbott Laboratories Feeding set for a peristaltic pump system
US8377000B2 (en) 2010-10-01 2013-02-19 Abbott Laboratories Enteral feeding apparatus having a feeding set
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
JP6219271B2 (ja) 2011-06-07 2017-10-25 パリオン・サイエンシィズ・インコーポレーテッド 治療の方法
WO2013010041A1 (en) 2011-07-12 2013-01-17 Cardeas Pharma Inc. Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
KR102092361B1 (ko) 2012-05-21 2020-03-23 인스메드 인코포레이티드 폐 감염을 치료하기 위한 시스템
CN102949379B (zh) * 2012-11-14 2014-11-05 中山大学 硫酸奈替米星吸入粉雾剂及其制备方法
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
CN104510726A (zh) * 2013-09-27 2015-04-15 张金华 一种用于清洁呼吸道系统的食盐干粉吸入剂
ES2981634T3 (es) 2014-05-15 2024-10-09 Insmed Incorporated Métodos para tratar infecciones micobacterianas pulmonares no tuberculosas
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
CN109172965B (zh) * 2018-10-24 2024-09-13 威海盛洁医疗科技有限公司 一种雾化颗粒大小可调节的雾化杯

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization

Also Published As

Publication number Publication date
AU778797B2 (en) 2004-12-23
CN1348377A (zh) 2002-05-08
HK1043732A1 (zh) 2002-09-27
EP1161247A1 (en) 2001-12-12
US6387886B1 (en) 2002-05-14
JP2002532430A (ja) 2002-10-02
PL348812A1 (en) 2002-06-17
NO20012978L (no) 2001-08-15
NO328594B1 (no) 2010-03-29
CA2355775A1 (en) 2000-06-22
NO20012978D0 (no) 2001-06-15
AU2370100A (en) 2000-07-03
HUP0105226A3 (en) 2003-03-28
BR9916296A (pt) 2004-06-29
WO2000035461A1 (en) 2000-06-22
CH693763A5 (de) 2004-01-30
SI20959A (sl) 2003-02-28
EP1161247A4 (en) 2002-05-15
CZ20012147A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
HUP0105226A2 (hu) Eljárás a súlyos krónikus bronchitis (bronchiectasia) kezelésére egy aeroszol formában lévõ antibiotikummal
HUP0203728A2 (hu) Formoterolt tartalmazó aeroszolkészítmény
KR920016086A (ko) 흡입용의 반응억제성 천식치료 활성을 갖는 비스테로이드성 소염제
HUP0103837A2 (hu) Pulmonáris beadásra alkalmas, száraz por formájú hatóanyag és eljárás az előállítására
HUP0103925A2 (hu) Formoterolt tartalmazó, stabilan tárolható hatóanyag-koncentrátum
BR0314763A (pt) Tratamento de infecções fúngicas
HUP0401066A2 (hu) Orális dózisforma, amely egy terápiás szert és egy ellentétes hatású szert tartalmaz és eljárás az előállítására
NO20053307L (no) Oralt administrerbart preparat for angivelse av virksomme stoffer i munnhulen og fremgangsmate for fremstilling derav.
HUP0301325A2 (hu) Stabilizált, gyógyászatilag hatékony kompozíció és ezt tartalmazó gyógyszerkészítmény és eljárás a kompozíció előállítására
DK0734249T3 (da) Hidtil ukendt og forbedret aminoglycosidformulering til aerosolisering
PT813424E (pt) Formas de dosagem farmaceutica oral que contem um inibidor da bomba de protoes e um agente antacido ou alginato
HUP0202311A2 (hu) Aeroszollá alakított fertőzésgátló, gyulladásgátló és vértolulást gátló szerek az orrmelléküreg-gyulladás kezelésében
HUP9802391A2 (hu) Inhaláló berendezés szalmeterol adagolására mért dózisban
HUP0302007A2 (hu) Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
DK1658047T3 (da) Spraytörret amorft pulver med en lav resterende fugtighed og udmærket lagerstabilitet
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
WO2004060903A3 (en) Aerosolizable pharmaceutical formulation for fungal infection therapy
NO20035274D0 (no) Farmasöytisk formulering bestående av plantetörrekstrakt med kalsiumbelegg
WO2005063777A8 (en) Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
ATE245967T1 (de) Trockene antibiotika-arzneiformen zur behandlung oberflächlichen geschwüren in der mundschleimhaut
AU2758201A (en) System and method for anonymous observation and use of premium content
YU16399A (sh) ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
AU2002215982A1 (en) Topical treatment of mastalgia with arometese inhibitors such as androstendione
Schermuly et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal